NCT07106736 (MAGIC-TIEMM) is a Phase 2 clinical trial of BCMA CAR-T in Multiple Myeloma, Newly Diagnosed, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT07106736?

NCT07106736 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT07106736?

Interventions in NCT07106736: BCMA CAR-T, GPRC5D/CD3 BiTEs.

What condition does NCT07106736 study?

NCT07106736 studies Multiple Myeloma, Newly Diagnosed.

Is NCT07106736 still recruiting?

NCT07106736 is currently recruiting now. Last updated 6 August 2025.

Last reviewed 2025-08-06 · How we verify

NCT07106736: MAGIC-TIEMM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

Recruiting now Phase 2 Last updated 6 August 2025

What this trial tests

Phase 2 trial testing BCMA CAR-T in Multiple Myeloma, Newly Diagnosed in 60 participants. Currently enrolling.

Timeline

10 August 2025

Primary endpoint
1 August 2027

1 August 2029

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	10 August 2025
Primary completion	1 August 2027
Estimated completion	1 August 2029
Sites	1 location across China

Drugs / interventions tested

BCMA CAR-T — full drug profile →
GPRC5D/CD3 BiTEs — full drug profile →

Conditions studied

Multiple Myeloma, Newly Diagnosed — all drugs for Multiple Myeloma, Newly Diagnosed →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

Adults 18 to 75, any sex, with Multiple Myeloma, Newly Diagnosed. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-center, clinical study to evaluate the efficacy and safety of a fully immunotherapy-based strategy guided by MRD-driven dynamic risk stratification in transplant-ineligible patients with newly diagnosed multiple myeloma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of BCMA CAR-T

Trials testing the same drug.

NCT07106684 — ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia · Phase 2 · recruiting
NCT07106710 — ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma · Phase 2 · recruiting
NCT04447573 — Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma · NA · unknown
NCT04626752 — CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma · EARLY_PHASE1 · unknown

Other recruiting trials for Multiple Myeloma, Newly Diagnosed

Currently open trials in the same condition.

NCT07106710 — ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma · Phase 2 · recruiting
NCT06758375 — Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients · Phase 2 · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07106736 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07106736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing